Background/Aims: The study was designed to explore the potential relationship of TLR4 and endothelial PAS domain-containing protein 1 (EPAS1) in vivo and vitro experiments. Methods: Bronchoalveolar lavage fluid (BALF) samples were collected from 55 chronic obstructive pulmonary disease (COPD) patients and 25 healthy subjects. The differential cell count was performed using Wright-Giemsa staining. The expression levels of TLR4 and TLR5 were detected by RT-qPCR. The levels of methylation and mRNA expression of EPAS1 were assayed by bisulfite sequencing PCR and real-time PCR. The correlation of TLR4 and EPAS1 was also analyzed in TLR 4-overexpressing endothelial cells. Results: The results showed that the number of neutrophils, lymphocytes and macrophages and expression of TLR 4 were significantly increased in lower respiratory tract of COPD patients. Moreover, decreased EPAS1 mRNA and increased EPAS1 promoter methylation were detected in COPD, which were closely associated with increased TLR4 expression. According to in vitro experiments, TLR 4 inhibited EPAS1 mRNA expression and promoted promoter methylation in endothelial cells. Conclusion: These findings suggest that TLR4 over-expression decreased EPAS1expression which contributes to the progress of COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long term poor airflow and irreversible pulmonary dysfunction that is usually both progressive and associated with an abnormal inflammatory response of the lungs. It is increasing year by year and become one of the leading causes of Morbidity. Cigarette smoke exposure is the biggest risk factor for COPD. Nicotinic acetylcholine receptor (nAChR) activation induced by tobacco and plays a role in the elevation of intracellular Ca 2+ concentration and subsequent cell proliferation and differentiation of airway smooth muscle cells (ASMCs) [1] . Various analyses have implicated that bacterial infections of the lower respiratory tract also play a major role in the pathogenesis and exacerbation of COPD [2] . Recently, several bacterial pathogens are recognized which are closely associated with COPD, among which gram-negative bacterial pathogens account for 88.7% and most are P. aeruginosa and A. baumanii [3] [4] [5] . Toll-like receptors (TLRs) have the ability to sense and combat invading pathogens by signaling the inflammatory response to Gram-negative bacteria through recognition of LPS and regulating the inducible expression of many cytokines, chemokines, adhesion molecules and acute phase protein. The Flagellar antigen of P. aeruginosa can be recognized by TLR-5 and LPS in the cell wall of gram-negative bacteria can effectively activate TLR-4. So, in this study, we first assessed the expression of TLR 4 and TLR 5 in COPD patients.
There are several important genes which are strongly associated with COPD. Integrative analysis of DNA methylation and gene expression data identifies endothelial PAS domaincontaining protein 1 (EPAS1) as a key regulator of COPD [6] . EPAS1 is located at chromosome 2 which is encoded by the EPAS1 gene in all kinds of mammals. It is protein and also called hypoxia-inducible factor-2 alpha (HIF-2 alpha). It is a transcription factor induced by hypoxia and involved in body response to oxygen level. Genes regulated by EPAS1 are enriched in biological processes including signaling, cell communications, and system development because EPAS1 downstream genes are significantly enriched in hypoxia responsive gene [6] . EPAS1 gene expression is reduced in many diseases [7, 8] .
With increasing concern that the microbial microenvironment is closely related with pulmonary diseases [9] , in our present study we investigated TLR4 and TLR5 expression in COPD by examining a total of 55 BALFs collected from COPD and 25 from healthy subjects. The relationships between TLR4 and EPAS1 promoter methylation and mRNA expression were verified by vivo and vitro experiment.
Materials and Methods
Subjects 55 patients with COPD (age 50 -55 years) diagnosed by a respiratory physician were included in the study. The clinical condition of the subjects included 30 acute exaggerated COPD patients (AECOPD) and 25 stable COPD patients (SCOPD). Chronic respiratory failure, asthma, coronary disease, and chronic metabolic diseases were excluded by a physician. 25 healthy subjects (non-smokers, age 50 -55 years) recruited from the general population, with no specific pulmonary diseases and none of them receiving any medication. Before the experiments, we obtained approval for our study from the Ethics Committee of Xi'an Jiaotong University and written informed consent from all participants involved in our study.
BALF samples collection
BALF were obtained by lavaging the airway with approximately 50 ml of 0.9% NaCl solution with help of the bronchoscope and approximately 60% lavage fluid was collected. The samples were centrifuged at 1,000 g for 10 min at 4°C. The cell pellets were resuspended with 0.9% NaCl solution, and later, some of the cell pellets were used for a differential cell count using Wright-Giemsa staining and some were used to extract RNA and DNA.
mRNA expression RNAs and DNAs were extracted simultaneously using E.Z.N.A ® Total DNA/RNA/Protein Kit (Omega, USA) according to manufacturer's protocols. TLR4, TLR 5 and EPAS1 were relatively quantified by SYBR Green real-time PCR Kit. Primers of TLR4 were 5'-GATGCTTCTTGCTGGCTGC-3' and 5'-ACCTTCATGGATGATGTTGGC-3'; TLR5 were 5'-ttgctcaaacacacctggacac-3' and 5'-ctgctcacaaagacaaacgat-3' [10] ; EPAS1 were 5'-TGTTGGGAGCGTTGGACGT-3' and 5'-ACCAAGGGTCAGGTAGTAAGTGGC-3' (Sangon, Shanghai, China).
RT-PCR reaction conditions were as follows: 95°C for 5 min, followed by 45 cycles of 95°C for 15 s and 60°C for 30 s. The fluorescence signal was acquired during the extension step at 60°C. A melting curve of the reaction system was drawn immediately after the reaction to analyze the specificity of the PCR products. Normalization of RNA expression data was achieved by comparing the gray values of target RNA with that of human GAPDH for each cycle. Quantitative analysis of target gene expression data was based on the 2 -ΔΔCT method.
DNA methylation assay by bisulfite sequencing
A total of 200 ng of genomic DNA from each sample was treated with bisulfite using EpiTect ® Bisulfite kit (Qiagen, China) according to the manufacturer's instructions. The genomic DNA was treated with sodium bisulfite to convert unmethylated cytosines to uracil. The DNA fragments containing CpG islands located in the promoter region of EPAS1 genes were amplified from the bisulfite-modified DNA by the primer pairs (5' AGTGTTTTGAGATTGTATGGTT 3' and 5' TATAACCCTTTAAAACRTTCAA 3',91-504). PCR was performed in a thermocycler (Bio-rad, USA) by Taq DNA Polymerase from Takara, China. The PCR products were purified using the agarose gel DNA extraction kit with subsequent cloning into pMD-18-T Vector (Takara, China) and transformation into DH-5α coli strain cells. The plasmid DNA isolated from positive bacterial clones was used for commercial sequencing of the cloned fragment of DNA. The results of bisulfite sequencing were assessed and presented using BiQ analyzer software.
Production of TLR 4 over expressed lentiviral vector
The Fragments encoding the coding sequence of human TLR4 were synthesized and cloned into EcoR I and BamH I of plasmid pLenO-GFP (10 kb). The constructed plasmid was verified by restriction enzyme mapping and DNA sequencing (Kangcheng, Shanghai, China). Production of lentivirus was performed using the combined ratio of packaging plasmid, Env plasmid, pRSV-Rev plasmid and transfer plasmid at 2:1:1:4 by using Endofectin-Lenti TM (GeneCopoeia Inc., USA). Titers were determined by flow cytometry (BD Pharmingen, USA) after infecting 293T cells. Human umbilical vein endothelial cells (HUVEC) cells were cultured in DMEM supplemented with 10% FBS at 37°C under 5% CO 2 in humidified air. 80% confluent monolayer cultures were infected with lentivirus. After overnight incubation, lentivirus was removed and fresh media added. Following 48 hours of culture, the cells were removed and positive cells were determined by indirect immunofluorescence.
MAPK inhibitor on EPAS-1 expression
HUVEC cells were cultured at 37°C with 5% O 2 , and then treated with MAPK inhibitor SB 203580 (500 nM, beyotine, China) for 30 min. MAPK inhibitor SB 203580 is a pyridinyl imidazole inhibitor widely used to inhibits the phosphorylation and activation of p38 MAPK (Santa Cruz Biotechnology, USA).
Western blot
Cells were disrupted by homogenization on ice and centrifuged at 4°C (12,000 g, 30 min) then the supernatants were collected. Equal amounts of protein (80 µg) were separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked in 5% (w/v) skim milk and incubated with antibodies against human p-p38 MAPK and p38 MAPK (1:1000; Santa cruz, USA) respectively. Blots were incubated with horseradish peroxidase conjugated secondary antibodies (Santa Cruz, USA) and detected by enhanced chemiluminescence (ECL) (Thermo Scientific, USA). The ratio of band intensity was calculated by using the value of band intensity of p-p38 and p38.
Statistical analysis
All data were expressed as means ± SEM. Differences between groups were examined for statistical significance by one-way analysis of variance (ANOVA) using SPSS 14.0 software (SPSS Inc., Chicago, USA). The correlation among EPSA1 and TLR-4 and TLR-5 were calculated using Pearson's correlation coefficient. P < 0.05 denoted that the difference was statistically significant.
Results

Pulmonary function of COPD patients and healthy subjects
Age and body mass index (BMI) of experiment subjects were most likely among the three groups according to our design. FEV1, FEV1 % and FVC, FVC % were predicted. FEV1/ FVC (%) significantly decreased in patients of AECOPD and SCOPD groups compared with the healthy group (Table 1, P < 0.01). However, there was no difference between AECOPD and SCOPD.
To assess the degree of lung inflammation of COPD patients, BALF samples were collected and differential cell counts were analyzed. The number of neutrophils dramatically increased in all COPD patients compared with healthy subjects (Fig. 1 ). There were also significant difference between AECOPD and SCOPD. The number of macrophages and lymphocytes significantly increased in AECOPD patients (P < 0.01).
TLR4 and TLR 5 expression increased in COPD patients
According to our unpublished data, the separation rate of P. aeruginosa and A. baumanii obviously increased in the above COPD samples. P. aeruginosa and A. baumanii were the main pathogens recognized by TLR-4 and TLR-5, so we observed TLR-4 and TLR-5 expression on cells in BALF. Real-time PCR results showed that TLR-4 expression significantly increased in all COPD patients compared to healthy subjects ( Fig. 2 , P < 0.01). Significant differences were observed between AECOPD and SCOPD. TLR-5 showed no significant differences (Fig. 2) .
EPAS1 mRNA expression decreased and promoter methylation increased in COPD patients
Real-time PCR results showed that EPAS1 mRNA expression was significantly decreased in all COPD patients compared to healthy subjects (Fig. 3A , P < 0.01). The Table 1 . Characteristics of all subjects. All data are expressed as means ± SEM. ** P < 0.01 vs. Healthy subjects. AECOPD, acute exaggerated COPD; SCOPD, stable COPD; FEV1, Forced expiratory volume in one second; FVC, forced vital capacity agarose gel electrophoresis of bisulfite sequencing PCR amplification products showed a single desired product of the same size as the expected target fragment. The average methylation rates of CpG were higher in all COPD patients than in healthy subjects ( Fig.  3B , P < 0.01). There was no obvious difference between AECOPD and SCOPD (Fig. 3A,  B ).
TLR4 were closely associated with EPAS1 mRNA expression and methylation
Using Pearson's correlation coefficient, TLR4 revealed a positive correlation with Fig. 2 . TLR 4 and TLR 5 expression were assayed by real-time PCR (n = 4). TLR 4 significantly increased in all COPD patients and showed difference between AECOPD and SCOPD. All data are expressed as means ± SEM. ** P < 0.01 vs. healthy group; ## P < 0.01 vs. SCOPD. Fig. 3 . EPAS1 mRNA expression and promoter methylation were assayed by real-time PCR (A) and BSP (B) (n = 3). EPAS1 abundance significantly decreased and the average methylation rates increased in all COPD patients compared to healthy subjects. There was no obvious difference between AECOPD and SCOPD. All data are expressed as means ± SEM. ** P < 0.01 vs. healthy group. 
P38 activation induced by TLR 4 inhibited EPAS1 mRNA expression
Both TLR 4 and EPAS1 were expressed on endothelial cells, so we further verify our results on endothelial cells. We found TLR 4-over expressed on endothelial cells, which showed that TLR4 over expression was markedly increased after lentiviral infection (Fig.  5A) . The average methylation rates of CpG were higher in TLR 4-over expressed cells than in control (Fig. 5B) . MAPK signaling plays an important role in inflammatory responses. To analyze the role of P38 MAPK in the TLR4-induced inhibition on EPAS1 mRNA expression, we cultured normal and TLR4 over-expressed cells with or without SB 203580 (500 nM) for 30 min. Then the cells were subjected to protein analysis for activated p38. The data showed that TLR 4 promoted the activation of P38. An increased activation of p38 was significantly inhibited by SB 203580 (Fig. 5C , P < 0.01). Over expression of TLR 4 inhibited the expression of EPAS1 mRNA, which was abrogated by SB 203580 (Fig. 5D , P < 0.01).
Discussion
COPD is characterized by inflammation and tissue destruction which are partially maintained by the innate immune defense system. The innate immune response in the airways involves the detection of pathogen or damage-associated molecular patterns by recognition receptors such as Toll-like receptors (TLRs) on cell surfaces. TLR 4 is most wellknown for recognizing LPS, a component present in Gram-negative bacteria and some Gram- positive bacteria (e.g. Neisseria sp.). TLR-4 participates in the defense against both viral and bacterial infections, and such infections may also contribute to disease progression of COPD.
In our study, we preliminary observed that the expression of TLR4 in lower airway of COPD patients was closely correlated with mRNA expression and DNA methylation of EPAS1, a hypoxia responsive transcription factor. At the low level of oxygen, EPAS1 was inducible to activate a series of downstream genes that allow cell survival as well as the re-establishment of O 2 supply. Hypoxia is not only a signifier of advanced COPD but also a key player in many of the maladaptive processes and the systemic comorbidities associated with COPD [11, 12] . The methylation level and mRNA expression of EPAS1 has severe implications on several disease processes, including stroke, tissue regeneration and cancer. Thus, the understanding of the condition and mechanisms of EPAS1 expression to disease would be very promising for treatment of disease.
In the present study, we also observed that TLR4 activated p38MAPK. As the pathology of COPD mediated by microorganisms, the pathogenic material (LPS) binds with TLR4 and phosphorylate and activate the MAPK pathway [13] . In present study, we observed when the cells were pretreated with MAPK inhibitor SB 203580, there was a down-regulation of p38 MAPK activation and up-regulation of EPAS1 expression. Therefore it suggested that the p38 MAPK pathway does not directly target EPAS1. Our result is not sufficient for the explanation of why TLR4 expression leading to activation of p38 MAPK but might be (i) decrease EPAS1 mRNA expression or (ii) lead to the methylation of EPAS1 gene, and that mechanism is more complicated. However, it is a possible mechanism that TLR4 inhibited the expression of EPAS1 mRNA through EPAS1 methylation. It would be interesting to precisely identify the complicated mechanisms of our results concerning the signaling of TLR4-induced methylation of EPAS1 in future studies.
Our study suggested that increased TLR4 decreased EPAS1 expression partly through MAPK signaling.
